TrialCancer science2018

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Nicola Fazio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.